Leproust, Twist Bioscience CEO, sells $58k in shares

Emily M. Leproust, Chief Executive Officer of Twist Bioscience Corp (NASDAQ:TWST), sold 2,265 shares of common stock on September 8, 2025, at a price of $25.76, for a total transaction value of $58,346. The sale comes as the $1.51B market cap company maintains a strong financial position, with InvestingPro data showing more cash than debt on its balance sheet and a healthy current ratio of 3.9x.

Following the transaction, Leproust directly owns 634,740 shares of Twist Bioscience Corp. The stock is currently trading near its 52-week low of $24.28, having declined about 46% year-to-date.

Leproust also holds options to purchase shares of common stock. These include options exercisable at $5.95 expiring on September 28, 2025; options exercisable at $8.82 expiring on September 28, 2027, with 150,879 shares; options exercisable at $26.66 expiring on November 18, 2028, with 266,539 shares; options exercisable at $23.33 expiring on October 23, 2029, with 131,290 shares; and options exercisable at $67.85 expiring on August 31, 2030, with 64,950 shares. For detailed analysis and additional insights on TWST’s valuation and future prospects, access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Twist Bioscience reported a notable 18% year-over-year increase in revenue for Q3 2025, reaching $96.1 million. Despite this revenue growth, the company experienced an adjusted EBITDA loss of $8 million, although this was an improvement from the previous fiscal year. In addition to financial results, Twist Bioscience announced the appointment of Trynka Shineman Blake to its board of directors, where she will also serve on the audit committee. Her extensive experience includes scaling Vistaprint’s business significantly during her tenure there.

In analyst updates, JPMorgan lowered its price target for Twist Bioscience from $33 to $25, maintaining an Underweight rating. TD Cowen also adjusted its price target from $58 to $36, while keeping a Buy rating, citing the company’s revised fiscal year 2025 guidance due to changes in Next-Generation Sequencing (NGS) revenue. Evercore ISI reduced its price target from $50 to $46, maintaining an Outperform rating, and noted strong performance in the NGS segment and solid gross margin results. These developments reflect the dynamic environment surrounding Twist Bioscience and its market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.